MAPT and Alzheimer disease: CSF biomarkers (CSF Aβ, CSF p-tau, and CSF t-tau) are used as an in-vivo measure of AD pathology; age and sex are used as a proxy of brain aging, and volumetric MRI as a proxy of brain neurodegeneration.